Haemonetics Co. (NYSE:HAE) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 29.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,436 shares of the medical instruments supplier's stock after purchasing an additional 13,920 shares during the quarter. Janus Henderson Group PLC owned about 0.12% of Haemonetics worth $4,720,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. TD Waterhouse Canada Inc. acquired a new position in shares of Haemonetics during the 4th quarter valued at about $25,000. Covestor Ltd raised its stake in Haemonetics by 146.8% during the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares during the period. Whittier Trust Co. acquired a new position in shares of Haemonetics in the 4th quarter valued at $62,000. Parkside Financial Bank & Trust grew its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after buying an additional 240 shares during the period. Finally, AlphaQuest LLC increased its holdings in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Up 1.5%

NYSE HAE opened at $70.41 on Monday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $95.53. The business has a 50 day moving average price of $62.92 and a two-hundred day moving average price of $71.21. The stock has a market cap of $3.54 billion, a PE ratio of 27.72, a P/E/G ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business had revenue of $330.60 million during the quarter, compared to analyst estimates of $329.38 million. During the same period last year, the business earned $0.90 EPS. The business's revenue was down 3.5% on a year-over-year basis. As a group, sell-side analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on HAE shares. Barrington Research reduced their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Raymond James reaffirmed a "strong-buy" rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. JMP Securities decreased their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Needham & Company LLC cut their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.